Truist Financial Cuts Genmab A/S (NASDAQ:GMAB) Price Target to $45.00

Genmab A/S (NASDAQ:GMAB) had its price target dropped by equities researchers at Truist Financial from $50.00 to $45.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 123.51% from the company’s previous close.

A number of other analysts have also commented on GMAB. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Trading Down 8.4 %

NASDAQ GMAB traded down $1.85 during trading hours on Tuesday, hitting $20.13. 1,480,995 shares of the company’s stock were exchanged, compared to its average volume of 885,455. The firm has a market cap of $13.32 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. The stock has a 50-day simple moving average of $21.30 and a 200 day simple moving average of $22.59. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Employees Retirement System of Texas bought a new position in shares of Genmab A/S in the fourth quarter valued at approximately $1,648,000. Mackenzie Financial Corp bought a new position in Genmab A/S in the 4th quarter valued at $689,000. GTS Securities LLC purchased a new stake in shares of Genmab A/S during the 4th quarter valued at $1,552,000. Vise Technologies Inc. raised its stake in shares of Genmab A/S by 41.7% during the 4th quarter. Vise Technologies Inc. now owns 12,892 shares of the company’s stock worth $269,000 after purchasing an additional 3,794 shares during the period. Finally, Voloridge Investment Management LLC grew its position in Genmab A/S by 102.4% during the fourth quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company’s stock valued at $23,170,000 after buying an additional 561,767 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.